Further analysis revealed that PD-L1 does not have sufficient predictive value, and other approaches were introduced, such as determination of mutational burden, mismatch repair deficiency, neoantigen immunogenicity, tumor microenvironment, infiltrating tumor cells, HLA heterozygosity, MHC-I mutations, autoimmune susceptibility, or the gut microbiome [11, 12]. This evidence concerns the gene CD274 and neoplasm.